Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Ingavirin ® dosed 60 mg daily is effective
and safe in the treatment of influenza and other acute respiratory viral infections in 13-17
years old patients.